- Home
- AVIR vs IMMR Comparison
AVIR vs IMMR Comparison
Compare AVIR & IMMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | IMMR |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.7M | 229.4M |
| IPO Year | 2020 | 1999 |
Fundamental Metrics
Financial Performance| Metric | AVIR | IMMR |
|---|---|---|
| Price | $3.15 | $6.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $12.25 |
| AVG Volume (30 Days) | 352.8K | ★ 591.0K |
| Earning Date | 11-12-2025 | 12-19-2025 |
| Dividend Yield | N/A | ★ 4.34% |
| EPS Growth | N/A | ★ 57.07 |
| EPS | N/A | ★ 2.04 |
| Revenue | N/A | ★ $163,133,000.00 |
| Revenue This Year | N/A | $988.71 |
| Revenue Next Year | N/A | $109.72 |
| P/E Ratio | ★ N/A | $3.38 |
| Revenue Growth | N/A | ★ 338.21 |
| 52 Week Low | $2.46 | $5.65 |
| 52 Week High | $4.02 | $10.72 |
Technical Indicators
Market Signals| Indicator | AVIR | IMMR |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 53.30 |
| Support Level | $2.99 | $6.83 |
| Resistance Level | $3.23 | $7.09 |
| Average True Range (ATR) | 0.09 | 0.26 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 74.55 | 56.59 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.